Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Next Previous
X
Search
Trial Profile

Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Diffuse large B cell lymphoma; Lymphomatoid granulomatosis; Lymphoproliferative disorders; Non-Hodgkin's lymphoma; Post-transplant lymphoproliferative disorder; T-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Results (n=11) of preliminary analysis assessing the activity and durability of nivolumab in LYG and other EBV-LPDs and NHLs, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 14 Jan 2023 Planned End Date changed from 1 Jun 2025 to 1 Jun 2031.
    • 14 Jan 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top